Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, et al. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Oncogene. 2023;42:1672-1684 pubmed publisher

Hino M, Iemura K, Ikeda M, Itoh G, Tanaka K. Chromosome alignment-maintaining phosphoprotein CHAMP1 plays a role in cell survival through regulating Mcl-1 expression. Cancer Sci. 2021;112:3711-3721 pubmed publisher

Xu J, Huang F, Yao Z, Jia C, Xiong Z, Liang H, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019;17:85 pubmed publisher

Haimovici A, Humbert M, Federzoni E, Shan Krauer D, Brunner T, Frese S, et al. PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression. Cell Death Differ. 2017;24:866-877 pubmed publisher

Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie L, et al. Regulation of Mcl-1 by constitutive activation of NF-κB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer. 2014;14:98 pubmed publisher

Ling X, Cao S, Cheng Q, Keefe J, Rustum Y, Li F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS ONE. 2012;7:e45571 pubmed publisher

Ricci M, Kim S, Ogi K, Plastaras J, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12:66-80 pubmed